Donafenib, also known as CM-4307, is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases with potential anticancer acivity. Donafenib is under clinical trials in China in patients with advanced hepatocellular carcinoma (HCC).
相关文献及参考
Richly, H., et al.: Int. J. Clin. Pharmacol. Ther., 41, 620 (2003),